
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3594564/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Spectral homogeneity of human platelets investigated by SERS. PLoS ONE, 2022, 17, e0265247.	2.5	2
2	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
3	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	27.0	381
4	NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring. PLoS ONE, 2021, 16, e0247102.	2.5	3
5	Spectral and time-resolved photoluminescence of human platelets doped with platinum nanoparticles. PLoS ONE, 2021, 16, e0256621.	2.5	0
6	The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases. Terapevticheskii Arkhiv, 2021, 93, 1470-1476.	0.8	2
7	Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. Journal of Global Antimicrobial Resistance, 2020, 21, 188-194.	2.2	21
8	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
9	Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment. Laser Physics Letters, 2020, 17, 045601.	1.4	17
10	Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by surface-enhanced Raman spectroscopy. Data in Brief, 2020, 29, 105145.	1.0	7
11	Prospects for Raman spectroscopy in cardiology. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.	784314 rg 1.4	BT ₉ /Overlock
12	Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Infektsionnye Bolezni, 2020, 18, 178-189.	0.4	0
13	Prospects for Raman spectroscopy in cardiology. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.	784314 rg 1.4	BT ₁ /Overlock
14	Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
15	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1215-1226.	27.0	457
16	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	4.1	63
17	Single human platelet study using surface-enhanced Raman spectroscopy as a perspective tool for antiplatelet therapy effectiveness prediction. , 2019, , .		1
18	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	7.1	35

#	Article	IF	CITATIONS
19	Growth differentiation factorâ€15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2018, 20, 1701-1709.	7.1	56
20	EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION. Urology Herald, 2018, 6, 30-37.	0.4	4
21	Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation. Urology Herald, 2018, 6, 50-56.	0.4	4
22	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVASâ€R</scp>): A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	4.4	139
23	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	27.0	5,629
24	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	2.7	32
25	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	3.9	53
26	Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	2.8	114
27	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	7.1	95
28	Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-D¢2DM). Diabetes Mellitus, 2017, 20, 403-419.	1.9	18
29	LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 68-75.	1.4	2
30	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
31	Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. International Journal of Infectious Diseases, 2016, 51, 47-55.	3.3	28
32	Sharing Data from Cardiovascular Clinical Trials — A Proposal. New England Journal of Medicine, 2016, 375, 407-409.	27.0	49
33	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	4.4	74
34	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQqO Therapy. Circulation: Heart Failure, 2016, 9, .	0 0 rgBT / 3.9	Overlock 10 83
35	Influence of Sacubitril/Valsartan (LCZ696)ÂonÂ30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248.	2.8	101
36	Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	260

#	Article	IF	CITATIONS
37	Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.	4.1	112
38	Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of Ñ€harmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus, 2016, 19, 443-456.	1.9	23
39	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	2.7	88
40	Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.	27.0	92
41	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
42	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 403-411.	8.6	196
43	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	2.2	80
44	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	2.8	118
45	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	2.2	187
46	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 2015, 373, 2247-2257.	27.0	1,856
47	P9: Efficacy and safety of simeprevir in treatment naÃ⁻ve HCV genotype 1-infected patients with METAVIR F2 fibrosis: QUEST-1 and QUEST-2 Phase III studies. Journal of Viral Hepatitis, 2014, 21, 25-26.	2.0	0
48	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825.	7.1	148
49	Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.	27.0	5,052
50	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 403-413.	13.7	431
51	Pharmacokinetic peculiarities of intravenous and oral ciprofloxacin administration in preoperative prophylaxis in patients with benign prostatic hyperplasia. Reviews on Clinical Pharmacology and Drug Therapy, 2014, 12, 64-66.	0.6	0
52	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2013, 15, 1062-1073.	7.1	358
53	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naÃ ⁻ ve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology, 2013, 58, 1918-1929.	7.3	255
54	Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 269-277.	4.4	91

#	Article	IF	CITATIONS
55	Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial. Gastroenterology, 2013, 144, S-374.	1.3	3
56	1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÃVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL. Journal of Hepatology, 2013, 58, S574.	3.7	76
57	Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice. European Heart Journal, 2013, 34, P2514-P2514.	2.2	0
58	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. New England Journal of Medicine, 2012, 367, 716-724.	27.0	274
59	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology, 2010, 52, 1201-1207.	7.3	63
60	247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY. Journal of Hepatology, 2010, 52, S104.	3.7	1
61	3-5 DAYS FLUOROQUINOLONES THERAPY IS MORE EFFECTIVE FOR ACUTE UNCOMPLICATED CYSTITIS THEN SINGLE DOSE FOSFOMYCIN: SYSTEMATIC REVIEW AND META-ANALYSIS. European Urology Supplements, 2008, 7, 268.	0.1	0
62	Quinolones for uncomplicated acute cystitis in women. The Cochrane Library, 2006, , CD003597.	2.8	34
63	Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2. International Journal of Antimicrobial Agents, 2006, 28, 4-9.	2.5	24
64	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1011-1020.	27.0	1,118
65	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1001-1010.	27.0	1,345